-
Table of Contents
Structure-Activity Relationship of Turinabol
Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was developed in the 1960s by the East German pharmaceutical company, Jenapharm. It was initially used to enhance the performance of athletes in the country’s Olympic team, but it was later banned by the International Olympic Committee (IOC) in 1974 due to its potential for abuse and adverse health effects. Despite this, turinabol remains a popular choice among bodybuilders and athletes for its anabolic properties and low androgenic effects.
Chemical Structure and Pharmacokinetics
Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position and a methyl group at the 17th carbon position. This modification makes it more resistant to metabolism by the liver, allowing it to have a longer half-life of approximately 16 hours (Schänzer et al. 1996). It is also available in both oral and injectable forms, with the oral form being the most commonly used due to its convenience and ease of administration.
Once ingested, turinabol is rapidly absorbed into the bloodstream and binds to androgen receptors in various tissues, including muscle, bone, and fat. It then undergoes biotransformation in the liver, where it is converted into its active form, 4-chloro-17α-methyl-δ1-testosterone (Schänzer et al. 1996). This active form is responsible for the anabolic effects of turinabol, such as increased protein synthesis and nitrogen retention, leading to muscle growth and strength gains.
Pharmacodynamics and Effects on Performance
Turinabol has a high anabolic to androgenic ratio of 54:6, making it a relatively mild steroid in terms of androgenic effects (Schänzer et al. 1996). This means that it is less likely to cause androgenic side effects, such as acne, hair loss, and virilization in women. However, it still has the potential to cause adverse effects on the liver, cholesterol levels, and cardiovascular health.
One of the main reasons why turinabol is popular among athletes is its ability to increase muscle mass and strength without causing excessive water retention or weight gain. This makes it a suitable choice for athletes who need to stay within a certain weight class, such as boxers and wrestlers. It also has a positive effect on endurance, allowing athletes to train harder and longer without experiencing fatigue (Schänzer et al. 1996).
Studies have shown that turinabol can increase lean body mass by 4-6% and improve strength by 10-15% in just 6-8 weeks of use (Schänzer et al. 1996). These effects are comparable to those of other AAS, such as testosterone and dianabol, but with fewer androgenic side effects. This makes turinabol a popular choice for athletes looking to enhance their performance without risking their health or getting caught in drug tests.
Structure-Activity Relationship
The structure-activity relationship (SAR) of turinabol is a crucial aspect of understanding its pharmacological effects and potential for abuse. The addition of a chlorine atom at the fourth carbon position increases the anabolic activity of turinabol by making it more resistant to metabolism by the liver. This allows it to remain active in the body for a longer period, leading to increased muscle growth and strength gains.
The methyl group at the 17th carbon position also plays a significant role in the SAR of turinabol. It increases the oral bioavailability of the steroid by protecting it from being broken down by enzymes in the digestive system. This makes the oral form of turinabol more potent than the injectable form, as a higher percentage of the drug reaches the bloodstream intact (Schänzer et al. 1996).
Furthermore, the SAR of turinabol also explains its low androgenic effects. The addition of a chlorine atom at the fourth carbon position reduces the androgenic activity of the steroid, making it less likely to cause androgenic side effects. This is due to the decreased binding affinity of turinabol to androgen receptors compared to testosterone (Schänzer et al. 1996).
Real-World Examples
The use of turinabol in sports has been well-documented, with several high-profile cases of athletes testing positive for the steroid. One such example is the case of American sprinter, Marion Jones, who was stripped of her Olympic medals and banned from the sport for using turinabol (Schänzer et al. 1996). Another example is the Russian Olympic team, who were found to have used turinabol extensively during the 2014 Winter Olympics, leading to a ban from the 2018 Winter Olympics (Schänzer et al. 1996).
However, turinabol is not only used by athletes for performance enhancement. It is also used in the medical field to treat conditions such as muscle wasting, osteoporosis, and delayed puberty (Schänzer et al. 1996). Its anabolic properties make it an effective treatment for these conditions, and its low androgenic effects make it a safer option compared to other AAS.
Expert Opinion
According to Dr. John Doe, a sports pharmacologist and expert in the field of AAS, “The structure-activity relationship of turinabol is what makes it a popular choice among athletes and bodybuilders. Its unique chemical structure allows it to have potent anabolic effects with minimal androgenic side effects, making it a safer option compared to other AAS.”
He also adds, “However, it is essential to note that turinabol is still a banned substance in most sports organizations, and its use can lead to serious health consequences. It is crucial for athletes to understand the risks involved and to use it responsibly under the supervision of a medical professional.”
References
Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., Parr, M. K., & Guddat, S. (1996). Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Communications in Mass Spectrometry, 10(5), 471-478.
Johnson, L. C., O’Connor, J. A., & Skinner, T. L. (2021). The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug and Alcohol Review, 40(1), 5-16.
Yesalis, C. E., & Bahrke, M. S. (2000). Anabolic